Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice

Blood (2024) 144 (Supplement 1): 120.

https://doi.org/10.1182/blood-2024-200732

Published: 2024

Journal Articles

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Gaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, Khrystal McBean, Lisa Ferguson, Jemma Larham, Jaimal Kothari, Naser Ansari-Pour, Sally Moore, Eileen Boyle, Udo Oppermann, Karthik Ramasamy, Angela Hamblin, Anjan Thakurta, Sarah Gooding

Blood (2023) 142 (Supplement 1): 644.

https://doi.org/10.1182/blood-2023-182734

Published: 2023

Journal Articles

Safety and Feasibility of a 16-Week Progressive Exercise Intervention in Treatment Naïve Chronic Lymphocytic Leukaemia

Frankie F Brown, Rebecca Oliver, Adam J Causer, Harrison D Collier-Bain, Annabelle Emery, Rachel Eddy, David Dutton, Josephine Crowe, Daniel Augustine, John Graby, Dan Rees, Daniela Rothschild Rodriguez, Oliver Peacock, Sally Moore, James Murray, James E Turner, John P Campbell

Blood (2023) 142 (Supplement 1): 6533.

https://doi.org/10.1182/blood-2023-186956

Published: 2023

Journal Articles

High Throughput Risk-Adapted Monoclonal Gammopathy Community Monitoring Program

Gaurav Agarwal, Lauren Campbell, Oluremi Carty, Sally Moore, Sarah Gooding, Jaimal Kothari, Julia Evans, Jemma Larham, Lisa Ferguson, Pamela Roberts, Elizabeth Bateman, Ross Sadler, Karthik Ramasamy

Blood (2023) 142 (Supplement 1): 5077.

https://doi.org/10.1182/blood-2023-190444

Published: 2023

Journal Articles

A Single Bout of Exercise Enhances the Efficacy of Rituximab Against Autologous Chronic Lymphocytic Leukaemia B Cells Ex Vivo By Transiently Increasing Natural Killer Cell Frequency in Blood, and Simultaneously Mobilises CD5 + CD19 + CD20 + B Cells into Blood

Harrison D Collier-Bain, Annabelle Emery, Adam J Causer, Frankie F Brown, Rebecca Oliver, David Dutton, Josephine Crowe, Daniel Augustine, John Graby, Shoji Leach, Rachel Eddy, Daniela Rothschild Rodriguez, Juliet C Gray, Mark S Cragg, Kirstie L Cleary, Sally Moore, James Murray, James E Turner, John P Campbell

Blood (2023) 142 (Supplement 1): 1179.

https://doi.org/10.1182/blood-2023-190009

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Blood (2023) 142 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2023-187202

Published: 2023

Journal Articles

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Blood (2021) 138 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2021-150177

Published: 2021

Journal Articles

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Blood (2021) 138 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2021-146061

Published: 2021

Journal Articles

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Faouzi Djebbari, Fotios Panitsas, Catherine Prodger, Fearn Davies, Kieran Burton, Akhil Khera, Grant Vallance, B.Sc., PhD, Sally Moore, Jaimal Kothari, Andy Peniket, MD, Karthik Ramasamy, MD PhD

Blood (2019) 134 (Supplement_1): 4768.

https://doi.org/10.1182/blood-2019-128139

Published: 2019

Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Blood (2019) 134 (Supplement_1): 861.

https://doi.org/10.1182/blood-2019-127992

Published: 2019

Journal Articles

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Oliver C Cohen, MBBS MRCP, Neil Rabin, Nicholas Counsell, Roger G Owen, MD PhD, Bilyana Popova, Oliver Schofield, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth Mary de Tute, PhD FRCPath, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Sally Moore, BSc, FRPATH, FRCP, MBBS, Paul Smith, PhD, Kwee L Yong

Blood (2016) 128 (22): 4508.

https://doi.org/10.1182/blood.V128.22.4508.4508

Published: 2016

Journal Articles

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Selina J Chavda, MBBS BSc MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Pavlina Mesiri, MSc, Nicholas Counsell, Jaimal Kothari, FRCPath, Antonia Bird, Ciaran Mariner, Anastasia Chew, MBBS, MRCP, FRCPATH, Katherine Clesham, MBBS, Sally Moore, BSc, FRPATH, FRCP, MBBS, Laura Percy, MBBS, MRCP, FRCPATH, Ali Rismani, MBBS, Shirley D'Sa, Rakesh Popat, Neil Rabin, Kwee L Yong

Blood (2016) 128 (22): 3465.

https://doi.org/10.1182/blood.V128.22.3465.3465

Published: 2016

Journal Articles

Single Centre Analysis Of Autologous Stem Cell Transplant Outcomes In Multiple Myeloma In 338 Consecutive Patients: Maintenance/Consolidation Is Associated With Superior Survival, But Early Relapse Is The Single Most Important Predictor Of Survival and May Override Genetic Risk

Paul M Maciocia, MRCP, Nicholas Counsell, Antonia Bird, Laura Percy, Sally Moore, BSc, FRPATH, FRCP, MBBS, Neil Rabin, Shirley D'Sa, MD, Manuel Rodriguez-Justo, Kwee L Yong, PhD

Blood (2013) 122 (21): 2159.

https://doi.org/10.1182/blood.V122.21.2159.2159

Published: 2013

Journal Articles

An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy,

Rakesh Popat, Jenny Dickson, Iftekhar Khan, Simon Cheesman, Laura Percy, Sally Moore, Shirley D'Sa, MD, Neil Rabin, Kwee Yong, PhD

Blood (2011) 118 (21): 4201.

https://doi.org/10.1182/blood.V118.21.4201.4201

Published: 2011

NARROW

Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Safety and Feasibility of a 16-Week Progressive Exercise Intervention in Treatment Naïve Chronic Lymphocytic Leukaemia

High Throughput Risk-Adapted Monoclonal Gammopathy Community Monitoring Program

A Single Bout of Exercise Enhances the Efficacy of Rituximab Against Autologous Chronic Lymphocytic Leukaemia B Cells Ex Vivo By Transiently Increasing Natural Killer Cell Frequency in Blood, and Simultaneously Mobilises CD5 + CD19 + CD20 + B Cells into Blood

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Single Centre Analysis Of Autologous Stem Cell Transplant Outcomes In Multiple Myeloma In 338 Consecutive Patients: Maintenance/Consolidation Is Associated With Superior Survival, But Early Relapse Is The Single Most Important Predictor Of Survival and May Override Genetic Risk

An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only